V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

• Text
• PDF

Abstract

Authors

D C Montefiori, B S Graham, J Zhou, J Zhou, R A Bucco, D H Schwartz, L A Cavacini, M R Posner